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Summary
Using geographic informa-
tion systems and economet-
ric modeling, we present the
first national study evalu-
ating the hospital quality
factors that attract patients
Purpose: To investigate whether patients requiring radiation treatment are prepared to
travel to alternative more distant centers in response to hospital choice policies, and
the factors that influence this mobility.
Methods and Materials: We present the results of a national cohort study using
administrative hospital data for all 44,363 men who were diagnosed with prostate can-
cer and underwent radical radiation therapy in the English National Health Service be-
tween 2010 and 2014. Using geographic information systems, we investigated the
extent to which men choose to travel beyond (“bypass”) their nearest radiation therapy
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for radiation therapy treat-
ment in health care markets.
We found that 1 in 5 men
bypassed their nearest radia-
tion therapy center for treat-
ment, especially those who
were younger and more
affluent. In the absence of
indicators reflecting treat-
ment quality, centers that
were early adopters of in-
tensity modulated radiation
therapy or that offered
shorter hypofractionated
treatment schedules were
more attractive to patients.
center, and we used conditional logistic regression to estimate the effect of hospital
and patient characteristics on this mobility.
Results: In all, 20.7% of men (nZ9161) bypassed their nearest radiation therapy cen-
ter. Travel time had a very strong impact on where patients moved to for their treat-
ment, but its effect was smaller for men who were younger, more affluent, and from
rural areas (P for interaction always <.001). Men were prepared to travel further to
hospitals that offered hypofractionated prostate radiation therapy as their standard
schedule (odds ratio 3.19, P<.001), to large-scale radiation therapy units (odds ratio
1.56, P<.001), and to hospitals that were early adopters of intensity modulated radia-
tion therapy (odds ratio 1.37, P<.001).
Conclusions: Men with prostate cancer are prepared to bypass their nearest radiation
therapy centers. They are more likely to travel to larger established centers and those
that offer innovative technology and more convenient radiation therapy schedules. In-
dicators that accurately reflect the quality of radiation therapy delivered are needed to
guide patients’ choices for radiation therapy treatment. In their absence, patient
mobility may negatively affect the efficiency and capacity of a regional or national ra-
diation therapy service and offer perverse incentives for technology adoption.  2017
The Author(s). Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Many countries have introduced policies that allow patients
to choose the hospital where they have their treatment (1,
2). Patients are expected to choose a hospital that delivers
better-quality care, and the resultant competition between
providers as they attempt to attract new patients is expected
to stimulate improvements in quality. However, for com-
plex treatments such as radiation therapy we have no data
to support whether patients are prepared to travel to alter-
native, more-distant centers, or the quality factors that in-
fluence this.
It is also debatable whether such policies are relevant in
cancer care, given the increasing centralization of cancer
services, which by its nature will reduce the choices
available to patients (3, 4). Treatment decisions are com-
plex, and the therapy itself may last for months, resulting in
significant physical and financial burden for those consid-
ering treatment at a more-distant hospital. Furthermore,
there is a lack of valid performance indicators that accu-
rately reflect the quality of cancer treatment, especially
radiation therapy.
However, radiation therapy has seen a relentless diffu-
sion of new technologies over the last decade, which has
shaped clinical practice in both the targeting and delivery of
treatment. It has been suggested that in certain health care
markets, clinicians and hospital providers are encouraged to
diversify practice through the integration and marketing of
new high-cost technologies (eg, proton beam therapy), to
attract new patients. However, this has been largely anec-
dotal, with little or no evidence in publicly funded health
systems (5, 6).
Using linked patient-level national datasets, geographic
information systems, and applied econometric modeling,
we investigated whether prostate cancer patients who had
radical radiation therapy in the English National Health
Service (NHS) “bypassed” their nearest radiation therapy
provider for treatment, as well as the provider and patient
characteristics associated with that mobility.
The NHS provides an ideal system for understanding the
impact of patient choice policies. It is a national, single-
payer, tax-based system in which care is free and not based
on ability to pay for insurance or treatment. The costs of
services are fixed under a national tariff, and providers are
therefore expected to compete on quality and not price (7).
Patients have access to all available NHS providers in
England, with no explicit restrictions on the choices
available.
Methods and Materials
We obtained individual patient-level data on all patients
diagnosed with prostate cancer between January 1, 2010,
and March 31, 2014 who subsequently underwent radiation
therapy in the English NHS. Data were retrieved from the
National Cancer Registration and Analysis Service and
linked at patient level to the National Radiotherapy Dataset
and Hospital Episode Statistics (8, 9). Patients who un-
derwent radiation therapy in the private sector were not
included in the analysis (<10% of eligible patients).
The National Radiotherapy Dataset provided informa-
tion on each patient’s radiation therapy treatment: start and
finish dates, treatment site (primary with or without
regional nodes), total dose, number of fractions, and radi-
ation therapy technique (intensity modulated radiation
therapy vs 3-dimensional conformal radiation therapy). The
National Cancer Registration and Analysis Service dataset
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provided information on cancer stage and the Hospital
Episode Statistics dataset on age and comorbidities. Cancer
severity was categorized according to a modified D’Amico
classification system (10-12). The patients’ place of resi-
dence was available as the Lower Layer Super Output Area
(LSOA), a geographic area that typically includes 1500
residents or 650 households (13, 14).
Travel times
The population-weighted centroids of the patients’ LSOAs
(used to define patient residence) and the full postal codes
for the hospitals where the radiation therapy was under-
taken were inputted into a geographic information system
(ESRI ArcGIS 10.3) to calculate travel times according to
the fastest route by car (using Ordnance Survey MasterMap
Integrated Transport Network).
Assessment of mobility
All radiation therapy treatment providers (nZ57) were
ranked according to the distance in terms of drive time by
car from the patient’s residence. The proportion of patients
not receiving care at their nearest provider (ranked >1)
were considered to be “by-passers” (15).
We identified for each radiation therapy center the number
of patients forwhom that centerwas nearest butwho had their
treatment elsewhered“leavers”dand also those patients for
whom another radiation therapy center was nearest but who
had their radiation therapy at that centerd“arrivers.” A
center was identified as being a “winner” or “loser” of pa-
tients if the difference between arrivers and leavers was
statistically significant (16). Patients receiving radiation
therapy at their nearest center were defined as “core users.”
Competition indices
For each center we also calculated a spatial competition
index (SCI) as a measure of “external competition”
(17, 18). The SCI provides a uniform metric that can be
used across all centers in England to factor in the demand
for services and the availability of alternative hospitals for
patients to choose. In this analysis the SCI for a radiation
therapy center was calculated according to both the number
of eligible patients within a 60-minute drive and the num-
ber of alternative radiation therapy centers within a 60-
minute drive for each eligible patient:
SCIiZ1
1
ni
Xni
jiZ1
1
kji
where radiation therapy center i has n eligible patients
within a 60-minute drive and patient j in center i has k
alternative radiation therapy centers within a 60-minute
drive. The SCI ranges theoretically from 0 for centers in
a monopoly environment to a value close to 1 for centers in
the most competitive environment.
Patient characteristics
Four patient-level variables were derived from the linked
dataset. First, patient age at the time of prostate cancer
diagnosis. Second, the Royal College of Surgeons Charlson
Score was used to identify the number of comorbidities
(19). Third, the Index of Multiple Deprivation (IMD) was
used as a measure of the patients’ socioeconomic depriva-
tion (20). The IMD was stratified into quintiles according to
the national distribution, such that 1 represents households
in the 20% least deprived and 5 in the 20% most deprived
LSOAs. Fourth, the patients’ area of residence was classi-
fied as urban or rural (21).
Hospital characteristics
At the start of the study there were 52 radiation therapy
centers across England. A further 5 centers opened during
the study period. In the absence of publicly reported per-
formance indicators for prostate cancer radiation therapy,
we created 4 hospital-level variables as proxies for quality,
which may make a hospital more attractive to patients when
considering where to have radiation therapy treatment.
These variables were informed by the peer-reviewed liter-
ature, in-depth qualitative interviews undertaken by the
study team with men previously treated for prostate cancer
in the United Kingdom, and The National Prostate Cancer
Audit organizational survey (22).
We identified the 28 “university teaching hospitals,” on the
basis of their membership of the Association of UK Univer-
sity Hospitals (23). Studies have demonstrated that teaching
hospital status is associated with higher quality for certain
interventions compared with non-teaching hospitals and
therefore may be preferentially chosen by patients (24-28).
Second, we labeled the 3 hospitals that were delivering
intensity modulated radiation therapy (IMRT) as a standard
of care at the start of the study period (2010) as “early IMRT
adopters.” There was emerging evidence at the time that this
technique delivered improved outcomes (reduced pelvic
toxicity) relative to standard 3-dimensional conformal tech-
niques (29, 30). In addition, IMRTwas already a standard of
care in countries such as the United States in 2010, which
may have prompted patients to seek treatment at centers that
offer this technique in the NHS (29, 30).
Third, we identified 8 centers that we classified as
“large-scale radiation therapy units” on the basis of the
number of linear accelerators on site. The median number
of linear accelerators across the 57 English NHS radiation
therapy centers was 4 (range, 2-12) (31). Centers with 8
linear accelerators on site (ie, in the top quintile based on
the distribution of linear accelerators) were considered to
meet this criteria. These centers may have been considered
preferentially by patients owing to their large capital and
staff infrastructure investment toward radiation therapy
facilities or wider reputation effects from being regional
centers.
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Fourth, we identified 4 centers that were delivering
hypofractionated radiation therapy (ie, higher dose per
treatment delivered over fewer total number of attendances)
as their standard dose-fractionation regimen for prostate
cancer at the start of the study period in 2010. Although a
dose of 74 Gy delivered over 37 treatments remains the
standard of care, hypofractionated regimens halve the
duration of treatment, from 8 weeks to 4 weeks (32, 33).
Statistical analysis
We used conditional logit regression to model the odds that a
patient moved to a particular hospital as a function of travel
time and hospital and patient characteristics (34, 35). We
created a data set that included for each patient a row for each
hospital providing prostate cancer radiation therapy at the
time of treatment (number of hospitals varied between 52
and 57 because 5 hospitals opened during the study period).
The dependent variable of the conditional logit model was a
dummy variable with a value of 1 for the hospital where a
patient had his treatment and a value of 0 otherwise.
Travel time was included in the model as the additional
time men had to travel beyond their nearest hospital to an
alternative hospital providing radiation therapy. In this way
we accounted for the variation in service configuration
across England. Per definition, additional travel time was
0 minutes if a patient had his radiation therapy in the
nearest radiation therapy center.
First, we modeled the effect of travel time and individual
hospital characteristics on the odds of moving to a partic-
ular hospital as part of a univariate analysis. In the second
model, we included both hospital characteristics and travel
time as part of a multivariate conditional regression model.
In the third model, we included travel time, hospital char-
acteristics, and the interactions of patient characteristics
with travel time. Patient characteristics included age, co-
morbidity, socioeconomic background, and urban or rural
residence. (We present the results of both models in Ta-
bles 3 and 4.) Stata version 14 was used to undertake the
statistical analyses (StataCorp, College Station, TX).
Results
Patient population
We identified 46,654 men diagnosed with prostate cancer
between January 1, 2010, and March 31, 2014 who subse-
quently received radiation therapy (Supplementary Material
Appendix 1; available online at www.redjournal.org). Of
these men, 44,860 received radical radiation therapy. A total
of 497 men were excluded because they lived outside En-
gland or could not be assigned to an NHS radiation therapy
provider. The final study cohort comprised 44,363 men, and
patient characteristics are presented in Table 1.
Patient mobility
In all, 9161 men (20.7%) “bypassed” or traveled beyond
their nearest radiation therapy center to an alternative,
more-distant center (Table 2); 5142 men (12.6%) bypassed
only 1 center, and 1125 men (2.5%) bypassed 5 or more
centers for treatment (Table 2). Figure 1 demonstrates the
net gains and losses of patients by individual prostate
cancer radiation therapy centers (nZ57) due to patient
mobility during the study period. Of the 57 centers, 19
(33.3%) were classified as “winners” and 25 (43.9%) as
“losers”; 13 centers had no statistically significant net gain
Table 1 Characteristics of 44,363 men undergoing radical
radiation therapy between 2010 and 2014 in the English
National Health Service
Characteristic n %
Age (y)
<65 12,951 29.2
65-69 9453 21.3
70-74 12,373 27.9
75 9586 21.6
Cancer severity
Advanced 620 1.8
Locally advanced 19,037 55.6
Intermediate localized 13,292 38.8
Low-risk localized 1276 3.7
Insufficient staging information (nZ10,138)
No. of comorbidities
0 34,368 77.5
1 9995 22.5
Index of multiple deprivation (national quintiles)
1 (least deprived) 10,832 24.4
2 10,780 24.3
3 9651 21.8
4 7336 16.5
5 (most deprived) 5764 13.0
Urban rural classification*
Urban 33,332 75.1
Rural 11,031 24.9
* See text for definition.
Table 2 Patient mobility of 44,363 men undergoing radical
radiation therapy between 2010 and 2014 in the English
National Health Service: Number of hospitals “bypassed” and
median travel time
No. of hospitals
bypassed*
No. of
patients (%)
Travel time (min),
median (interquartile range)
0 35,202 (79.4) 20.7 (12.1-32.7)
1 5142 (12.6) 38.3 (23.4-53.6)
2 1764 (4.0) 44.0 (22.9-59.6)
3 822 (1.9) 46.7 (34.7-60.6)
4 308 (0.7) 55.6 (43.3-67.3)
5 1125 (2.5) 52.9 (36.8-89.8)
* Hospitals are considered to be “bypassed” if a man has radiation
therapy in a hospital that is further away from his place of residence in
terms of travel time by car.
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or loss of patients. Some of the “winners” were treating 500
or more patients than expected if they had been operating
solely on men for whom they were the nearest center.
Conversely, some of the “losers” were treating nearly 400
fewer procedures than expected. When considering the
degree of external competition faced by each center, centers
experiencing the largest net gains or losses were predomi-
nantly located in the most competitive areas (SCI between
0.70 and 1) (Fig. 2).
Impact of travel time and patient and hospital
characteristics on patient mobility
Travel time had a very strong impact on the odds that a
patient traveled to a particular hospital to receive radiation
therapy in the univariate and multivariate conditional
regression models (Tables 3 and 4). The odds of a patient
traveling to a hospital that was up to 10 minutes further
away than the patient’s nearest radiation therapy provider
was found to be on average 72% smaller (odds ratio [OR]
of 0.28) according to a conditional logit model that only
included additional travel time (Table 3, model 1). The
odds of a patient traveling to a particular hospital decreased
markedly as the additional travel time increased.
The results of the univariate analysis assessing the
impact of hospital characteristics on the odds of traveling
further to a particular hospital are presented in Table 3
(model 1). When considering the impact of hospital char-
acteristics on mobility patterns of patients as part of a
multivariate regression model including travel time and
patient characteristics, men were 3.19 times more likely to
travel to a particular radiation therapy center if it offered
hypofractionated radiation therapy as standard (Table 4,
model 3). In addition, patients were 1.56 times more likely
to travel to a center classified as a large-scale radiation
therapy unit, and 1.37 times more likely to travel to a center
if it was an established IMRT center. There was a small
but significant increase in the likelihood that patients
traveled to a specific center if it had university hospital
status (OR 1.19).
The addition of patient characteristics as interaction terms
into our model showed that the impact of travel time was
smaller for men whowere younger and for thosewho lived in
more affluent or rural areas, because the ORs expressing the
interaction terms are greater than 1 (Table 4, model 3). The
greater the size of the interaction term value, the larger its
attenuating effect on the impact of travel time. For example,
compared with having the radiation therapy at the nearest
provider, for men classified as living in urban and less
affluent areas, who are aged 65 years, and who have
comorbidities, the odds of traveling to a hospital that was up
to 10 minutes further away was estimated to be 82% smaller
(OR 0.18). The corresponding figure for men from rural
areas (keeping all other patient characteristics the same as
described) was 60% smaller (OR 0.40Z 0.18 2.23, based
on multiplying the OR of the main effect of additional travel
time with the OR of the interaction term). This implies that
men from rural areas have a greater odds of traveling to an
alternative hospital up to 10 minutes further away compared
with men from urban areas. Different patient characteristics
attenuate the effect further. For example, men from both
rural and affluent areas (positive interaction terms) have an
even greater odds of traveling to an alternative hospital up to
10 minutes further away (keeping all other patient charac-
teristics the same, OR 0.51Z 0.16 2.23 1.26) compared
with men from urban and less affluent areas.
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Fig. 1. Net gains and losses of patients by each radiation therapy center (blue bars) due to patient mobility between 2010
and 2014. (A color version of this figure is available at www.redjournal.org.)
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Discussion
There is limited evidence about what factors inform and
influence cancer patients’ choice of treatment provider (1).
In this study we demonstrate that in the United Kingdom
NHS, 1 in 5 patients who have radiation therapy treatment
“bypass” their nearest radiation therapy center. Travel time
had a very strong impact on where patients received their
treatment, but this effect was smaller for men who were
younger, more affluent, or living in rural areas. Men were
more likely to travel to centers that offered shorter hypo-
fractionated radiation therapy regimens as standard for
Table 3 Impact of travel time and hospital characteristics on patient mobility in 44,363 men undergoing radical radiation therapy
between 2010 and 2014 in the English National Health Services
Parameter
Unadjusted OR
(model 1)* 95% CI Py
Adjusted OR
(model 2)z 95% CI Py
Impact of additional travel time (min) 1 <.001 1 <.001
<10 0.28 0.27-0.29 0.27 0.26-0.28
11-30 0.07 0.06-0.07 0.06 0.05-0.06
31-60 0.006 0.005-0.06 0.005 0.004-0.005
>60 0.0002 0.0001-0.0002 0.0002 0.0001-0.0002
Impact of hospital characteristics
University hospital 1.28 1.26-1.31 <.001 1.18 1.14-1.23 <.001
Large-scale RT unit 1.95 1.91-1.99 <.001 1.55 1.48-1.62 <.001
Early adopter of IMRT 1.15 1.11-1.20 <.001 1.37 1.30-1.46 <.001
Hypofractionated treatment (standard) 1.73 1.68-1.78 <.001 3.10 2.92-3.28 <.001
Abbreviations: CI Z confidence interval; IMRT Z intensity modulated radiation therapy; OR Z odds ratio; RT Z radiation therapy.
* Model 1 presents unadjusted ORs from the univariate analysis assessing the impact of additional travel time and hospital characteristics on the odds
that a patient travels to a particular hospital.
y
P value based on likelihood ratio test.
z Model 2 presents adjusted ORs from the multivariate conditional logit analysis assessing the impact of both additional travel time and hospital
characteristics on the odds that a patient travels to a particular hospital.
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Fig. 2. Graph demonstrating the impact of competition (measured by the spatial competition index [SCI]) on the net gain or
loss of patients for radiation therapy centers between 2010 and 2014. SCI score Z 0: Hospital facing weakest competition;
SCI scoreZ 1: Hospital facing strongest competition; size of circleZ number of men expected to have radiation therapy at
center; blueZ centers classified as “winners”; greenZ centers classified as “losers”; orangeZ centers with no statistically
significant gain or loss of patients; red Z centers offering hypofractionated radiation therapy as standard.
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prostate cancer, larger established radiation therapy units,
and those centers that utilized IMRT earlier. Mobility be-
tween providers resulted in winners and losers, with some
centers treating hundreds more patients each year than
expected if they only treated local patients.
These findings are relevant across a range of elective
secondary care cancer services in countries that have
introduced patient choice of provider policies (1). A sub-
stantial number of patients were prepared to bypass their
nearest radiation therapy center despite the absence of
comparative provider-level performance information
relating to the quality of radiation therapy treatment and the
prolonged duration of treatment.
The routine availability of hypofractionated radiation
therapy for prostate cancer was the strongest hospital-level
driver of patient mobility. It is not possible to say whether
patients were prepared to travel further to these centers
because hypofractionated radiation therapy is more
Table 4 Impact of travel time and hospital and patient characteristics on patient mobility in 44,363 men undergoing radical radiation
therapy between 2010 and 2014 in the English National Health Service
Parameter Adjusted OR (model 3)* 95% CI Py
Impact of additional travel time (min)z 1 <.001
<10 0.18 0.16-0.20
11-30 0.04 0.04-0.05
31-60 0.002 0.002-0.003
>60 0.00006 0.00004-0.00009
Impact of hospital characteristics
University hospital 1.19 1.14-1.23 <.001
Large-scale RT unit 1.56 1.49-1.63 <.001
Early adopter of IMRT 1.37 1.30-1.45 <.001
Hypofractionated treatment (standard) 3.19 3.01-3.37 <.001
Difference in impact of additional travel time
for selected patient characteristicsx
Interaction terms
Younger patients (<65 y) <.001
<10 1.17 1.07-1.28
11-30 1.10 1.00-1.21
31-60 1.42 1.15-1.76
>60 2.01 1.46-2.77
Patients without comorbidities NS
<10 0.95 0.87-1.03
11-30 0.93 0.85-1.02
31-60 0.96 0.79-1.17
>60 1.24 0.94-1.63
Patients from more affluent areas (IMD 1 or 2) <.001
<10 1.26 1.17-1.36
11-30 1.20 1.10-1.29
31-60 1.08 0.92-1.29
>60 1.31 1.05-1.62
Patients from rural areas <.001
<10 2.23 2.04-2.44
11-30 2.21 2.03-2.42
31-60 3.21 2.72-3.79
>60 1.87 1.51-2.33
McFadden’s pseudo R2 0.82
Abbreviations: IMD Z Index of Multiple Deprivation; NS Z nonsignificant. Other abbreviations as in Table 3.
* Model 3 presents adjusted odds ratios from the multivariate conditional logit analysis assessing the impact of additional travel time, hospital
characteristics, and patient characteristics on the odds that a patient travels to a particular hospital.
y
P value based on likelihood ratio test.
z Note that the adjusted ORs for the impact of additional travel time in model 3 relates to a particular patient group: older men (65 years), with
comorbidity (Charlson 1), from less affluent (IMD 3-5) and urban areas.
x The impact of selected patient characteristics on additional travel time is presented as interaction terms. These should be multiplied with the
corresponding adjusted OR for additional travel time to formulate a new OR. Interaction terms can be used in any combination to assess the effect of
different patient characteristics on the odds that a patient travels to a particular hospital. For example, the adjusted ORs presented (z) relate to older men
(65 years), with comorbidity (Charlson 1), from less affluent (IMD 3-5) and urban areas. To calculate the new OR for younger and more affluent men
traveling 11-30 minutes, but who still have comorbidity and live in urban areas, multiply 0.04 (travel time adjusted OR for 11-30 minutes) by the
corresponding interaction term for men who are affluent (1.20) and men living in rural areas (2.21). The new odds ratio is 0.04  1.20  2.21Z 0.11.
That is, men with these patient characteristics have a greater odds of traveling up to 30 minutes to a particular hospital.
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convenient or because patients considered these centers to
be innovative and therefore potentially better (36). How-
ever, the potential desire for treatment of shorter duration
correlates with our study findings that travel time has a very
strong impact on the choices that patients make. In addi-
tion, previous research has shown that patients are reluctant
to undergo radiation therapy compared with other prostate
cancer treatment modalities, owing to its prolonged dura-
tion (37).
Patients in our cohort were more likely to travel to the 3
centers labeled as early adopters of IMRT, despite rapid
expansion in the availability of IMRT across centers in En-
glandduring the studyperiod (38, 39). This suggests that there
is a wider reputation effect associated with being an early
adopter of innovation and that patients may have considered
these centers to be at the forefront of technology (40, 41). To
illustrate this point, all 3 established IMRT centers were also
amongst the first adopters of stereotactic body irradiation in
England (12). Similarly, patients were more likely to travel to
larger-scale radiation therapy units, which may have had a
wider reputation as being a regional center of excellence for
radiation therapy or cancer care more generally.
The patterns of mobility observed has resulted in large
and unexpected shifts in market share. Radiation therapy
centers located in the most competitive areas had signifi-
cant gains and losses of patients (Fig. 2). In the NHS,
funding follows the patient (7), and therefore centers losing
patients may have to cease providing that service owing to
lost income. Such an eventuality has already transpired for
surgical centers providing radical prostatectomy, several of
which have closed in the last 5 years (42). This pattern of
winners and losers also highlights the inefficiency and
wasted capacity within the current radiation therapy ser-
vice, which may further increase as a result of the current
drive toward opening new radiation therapy centers across
England (5 opened during the study period) to improve
access to treatment. Equally, the impact on service capacity
(eg, waiting times) needs to be considered for those centers
treating significant numbers of out-of-area patients.
Appropriate implementation of advanced radiation
technologies
In the absence of performance indicators, centers that
diversify their clinical practice (eg, through the integration of
new technology) are potentially more attractive to patients.
In the United States, competition has been a key driver in the
rapid expansion of innovative radiation therapies, such as
IMRT, proton beam therapy, and Cyberknife, for the man-
agement of prostate cancer to maintain market share and
attract new patients. This has occurred at significant addi-
tional cost without any clear evidence for benefits to patients
over existing standards of care (6,30,43-46).
To avoid similar patterns of technology adoption for
radiation therapy across different health systems, we
recommend the use of formal health technology assessment
processes to support decision making regarding the
integration of new technologies in publicly funded systems
(5, 47). In contrast to new cancer drugs, radiation therapy
has remained beyond the remit of health technology
assessment (5). The Health Economics in Radiation
Oncology project, which is being carried out under the
auspices of the European Society for Radiotherapy and
Oncology, is attempting to define economic frameworks for
assessing the clinical and economic benefit of new radiation
therapy technologies and is still in its infancy (48).
There is also a necessity to develop valid performance
indicators for radiation therapy to guide patient decision
making and potentially stimulate improvements in treat-
ment outcomes through “quality competition” as patients
are responsive to perceived differences in quality (49). This
is important, given the increasing reliance on unsubstanti-
ated web- and media-based cancer information, especially
for new technologies (50-52). A series of process indicators
have been proposed by professional bodies, but these are
hard for patients to interpret (53, 54). Although outcome
measures are preferable, an important caveat is that these
can only be published following a lag period (toxicity
measures at 1 and 5 years) (55).
Methodologic limitations
Our modelling of patient mobility used centroids of the
LSOAs, small geographic regions typically made up of
approximately 650 households, to represent the location of
the patients’ residence. This approach has been used in
previous studies of patient mobility in England (56).
However, it is likely that the “noise” added to the travel
times will have attenuated rather than enhanced the
observed relationships. Our model uses average drive times,
which is the standardized methodology for these analyses
and considered superior to straight-line distance. However,
we do acknowledge that drive times are variable depending
on the time of day, which may affect patients’ decision
making. In addition, public transport times were not
available for this analysis.
We have not included waiting times as a factor influ-
encing provider choice, because these were not publicly
available for individual centers. Some patients may have
considered moving to alternative providers to receive
quicker treatment; however, extensive efforts have been
made in the English NHS to ensure prompt diagnosis and
treatment of suspected cancer patients through a system of
defined targets (57, 58). In 2014/2015 95.3% of people
treated for urologic cancers in the NHS began their first
definitive treatment within the 31-day target (59). Other
potential determinants of mobility, such as care giver/work
location, were not available in our dataset, and we were
unable to assess the effect of disease severity owing to
incomplete staging data. However, the overall impact on
our observed patterns of mobility is likely to be small in
the context of up to 20% of patients bypassing their
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nearest provider. The overall predictive probability of our
model, despite these exclusions, is very high, 82% (note
models with values above 60% for goodness of fit esti-
mation are considered to have a high degree of explana-
tory power) (60).
Conclusions
Menwith prostate cancer are prepared to bypass their nearest
provider for radical radiation therapy, particularly those who
are younger and more affluent. They are more likely to travel
to larger established centers and those that offer innovative
technology and shorter radiation therapy schedules. Patient
mobility varies significantly across regions and between
centers and is mainly evident in areas where competition
between providers is strongest. This in itself implies that
competition as a mechanism to stimulate improvements in
the quality of care can only work in specific parts of the
country. Indicators that accurately reflect the quality of ra-
diation therapy delivered are essential to guide patients’
choices for radiation therapy treatment. In their absence,
patient mobility may negatively affect the efficiency and
capacity of regional or national radiation therapy services
and offer perverse incentives for technology adoption even in
publicly funded health systems.
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